Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.

Autor: Bol KF; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands., Aarntzen EH; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.; Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands., Pots JM; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., Olde Nordkamp MA; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., van de Rakt MW; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., Scharenborg NM; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., de Boer AJ; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., van Oorschot TG; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., Croockewit SA; Department of Hematology, Radboud University Medical Centre, Nijmegen, The Netherlands., Blokx WA; Department of Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands., Oyen WJ; Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands., Boerman OC; Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands., Mus RD; Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands., van Rossum MM; Department of Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands., van der Graaf CA; Department of Pulmonary Diseases, Radboud University Medical Centre, Nijmegen, The Netherlands., Punt CJ; Department of Medical Oncology, Academic Medical Centre, Amsterdam, The Netherlands., Adema GJ; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., Figdor CG; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., de Vries IJ; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands., Schreibelt G; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. Gerty.Schreibelt@radboudumc.nl.

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2016 Mar; Vol. 65 (3), pp. 327-39. Date of Electronic Publication: 2016 Feb 10.

Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection.

Autor: Van der Graaf CA; Department of Internal Medicine (463), Radboud University Nijmegen Medical Center, PO BOX 9101, 6500 HB Nijmegen, The Netherlands., Netea MG, Morré SA, Den Heijer M, Verweij PE, Van der Meer JW, Kullberg BJ

Publikováno v: European cytokine network [Eur Cytokine Netw] 2006 Mar; Vol. 17 (1), pp. 29-34.

Recognition of fungal pathogens by toll-like receptors.

Autor: Netea MG; Department of Medicine, Radboud University Nijmegen Medical Center, and Nijmegen University Center for Infectious Diseases, Nijmegen, The Netherlands. M.Netea@aig.umcn.nl, Ferwerda G, van der Graaf CA, Van der Meer JW, Kullberg BJ

Publikováno v: Current pharmaceutical design [Curr Pharm Des] 2006; Vol. 12 (32), pp. 4195-201.

Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells.

Autor: Netea MG; Department of Medicine,, University Medical Center St. Radboud, Nijmegen, The Netherlands., Sutmuller R, Hermann C, Van der Graaf CA, Van der Meer JW, van Krieken JH, Hartung T, Adema G, Kullberg BJ

Publikováno v: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2004 Mar 15; Vol. 172 (6), pp. 3712-8.

The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis.

Autor: Netea MG; Department of Medicine, Division of General Internal Medicine, University Medical Center St. Radboud, Nijmegen, The Netherlands., Van Der Graaf CA, Vonk AG, Verschueren I, Van Der Meer JW, Kullberg BJ

Publikováno v: The Journal of infectious diseases [J Infect Dis] 2002 May 15; Vol. 185 (10), pp. 1483-9. Date of Electronic Publication: 2002 Apr 30.